Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of...
Neuroendocrine Cancer UK is excited to announce that its publication “Patient Perspectives, from Diagnosis Through Treatments and Beyond”, co-authored by Catherine Bouvier and Nicola Jervis, has been published in Current Opinion in Endocrine and Metabolic Research...
Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of Merkel cell carcinoma (MCC) is not known. Factors strongly...
21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC. Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...
